Similar companies
Company | Revenue | |
---|---|---|
No data for previous quarter available yet. |
Income Statement (USD)
Q2 '24 | QoQ | |
---|---|---|
Revenue | 124M | 64.6% |
Gross Profit | 39M | 7.4% |
Cost of Revenue | 16M | 93.6% |
Operating expense | 53M | 78.2% |
Net Income | -13M | 92.8% |
EBITDA | -7.9M | 95.9% |
Balance Sheet (USD)
Q2 '24 | QoQ | |
---|---|---|
Total Assets | 318M | 2.2% |
Total Liabilities | 112M | 5.6% |
Total Equity | 206M | 6% |
Shares Outstanding | 40M | 0% |
Cash Flow (USD)
Q2 '24 | QoQ | |
---|---|---|
Cash from operations | 5M | 139.9% |
Cash from investing | -2.3M | 107.9% |
Cash from financing | -5M | 820.5% |
EPS
Financial Highlights for Angiodynamic in Q2 '24
Angiodynamic reported a revenue of 124M, which is a 64.6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 39M, marking a 7.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 16M, a -93.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 53M, showing a -78.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -13M, showing a 92.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -7.9M, showing a 95.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Angiodynamic with growth in revenue, gross profit, and net income.